Explore the capacity of 2 dosage levels of ACC-001 plus QS-21 to remove brain fibrillar Aβ in subjects with early AD. 2 years [clinicaltrials_resource:a76c4dc04d7b744dd075b16dc6e68731]
ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Explore the capacity of 2 dosage levels of ACC-001 plus QS-21 to remove brain fibrillar Aβ in subjects with early AD. 2 years [clinicaltrials_resource:a76c4dc04d7b744dd075b16dc6e68731]
ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
Bio2RDF identifier
a76c4dc04d7b744dd075b16dc6e68731
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a76c4dc04d7b744dd075b16dc6e68731
measure [clinicaltrials_vocabulary:measure]
Explore the capacity of 2 dosa ...... Aβ in subjects with early AD.
time frame [clinicaltrials_vocabulary:time-frame]
description
ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
identifier
clinicaltrials_resource:a76c4dc04d7b744dd075b16dc6e68731
title
Explore the capacity of 2 dosa ...... ubjects with early AD. 2 years
@en
type
label
Explore the capacity of 2 dosa ...... c4dc04d7b744dd075b16dc6e68731]
@en